Combination of dendritic cell-based vaccination and immune checkpoint blockade for malignant mesothelioma immunotherapy
Grant Data
Project Title
Combination of dendritic cell-based vaccination and immune checkpoint blockade for malignant mesothelioma immunotherapy
Principal Investigator
Dr Tan, Zhiwu
(Principal Investigator (PI))
Co-Investigator(s)
Professor Chen Zhiwei
(Co-Investigator)
Duration
24
Start Date
2017-06-01
Completion Date
2020-02-28
Amount
1180856
Conference Title
Combination of dendritic cell-based vaccination and immune checkpoint blockade for malignant mesothelioma immunotherapy
Keywords
AAV, DNA vaccine, immune checkpoint, immunotherapy, malignant mesothelioma, PD-1
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
04151266
Grant Type
Health and Medical Research Fund - Full Grant
Funding Year
2016
Status
Completed
Objectives
Malignant mesothelioma is a rather aggressive cancer caused by exposure of mesothelial cells to airborne asbestos. It has received much attention worldwide because of asbestos control and huge financial compensation. Due to Hong Kong's large consumption of asbestos in the 1960s, we are believed to be facing its peak incidence. Because of the limitation of survival benefit and side effect from chemotherapy, immunotherapy approaches are highly desirable. The overall objectives of the proposed study is to reprogram immunotherapeutic mesothelioma-specific CD8+ T cell immunity by combination of induction and modulation.